Skip to main content
Top
Published in: Journal of Parasitic Diseases 4/2021

01-12-2021 | Leishmania | Original Article

India’s performance in controlling Visceral Leishmaniasis as compared to Brazil over past three decades: findings from global burden of disease study

Authors: Deepak Dhamnetiya, Ravi Prakash Jha, Shalini, Krittika Bhattacharyya

Published in: Journal of Parasitic Diseases | Issue 4/2021

Login to get access

Abstract

Visceral leishmaniasis (VL) is a neglected tropical disease which contributes to the mortality and morbidity significantly in India and Brazil. This study was planned to compare the trends of incidence, prevalence, death and disability-adjusted life years (DALY) of VL burden in India and Brazil from 1990 to 2019 using Global burden of disease study (GBD) data. The metrics are presented as age-standardized rates per 100,000 inhabitants with their respective uncertainty intervals (95% UI) and relative percentages of change. The decline in the Incidence rate is more in case of India (16.82 cases per 100,000 in 1990 to 0.60 cases in 2019) as compared to Brazil (3.12 cases per 100,000 in 1990 to 2.65 cases in 2019). The annualized rate of change in number of prevalent cases for India is − 0.95 (95% UI − 0.98 to − 0.91) whereas for Brazil it is − 0.06 (95% UI − 0.41 to 0.52). The annualized rate of change in number of DALY for India is − 0.94 (95% UI − 0.96 to − 0.92) whereas for Brazil it is − 0.09 (95% UI − 0.25 to 0.28). The annualized rate of change in number of deaths for India is − 0.93 (95% UI − 0.95 to − 0.92) whereas for Brazil it is increasing i.e. 0.04 (95% UI − 0.12 to 0.51). India achieves significant reduction in the age standardized incidence, prevalence, mortality and DALY of VL as compared to Brazil during the period of 1990 to 2019. A multi-centric study is required to assess bottleneck in the existing strategies of VLSCP in Brazil.
Literature
go back to reference Alvar J, Molina R, San Andre´s M, Tesouro M, Nieto J, Vitutia M, et al (1994) Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 88:371–378CrossRef Alvar J, Molina R, San Andre´s M, Tesouro M, Nieto J, Vitutia M, et al (1994) Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 88:371–378CrossRef
go back to reference Berman JD (1997) Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684–703CrossRef Berman JD (1997) Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684–703CrossRef
go back to reference da Rocha ICM, Dos Santos LHM, Coura-Vital W, da Cunha GMR, Magalhães FDC, da Silva TAM (2018) Effectiveness of the Brazilian Visceral Leishmaniasis Surveillance and Control Programme in reducing the prevalence and incidence of Leishmania infantum infection. Parasit Vectors 11:586CrossRef da Rocha ICM, Dos Santos LHM, Coura-Vital W, da Cunha GMR, Magalhães FDC, da Silva TAM (2018) Effectiveness of the Brazilian Visceral Leishmaniasis Surveillance and Control Programme in reducing the prevalence and incidence of Leishmania infantum infection. Parasit Vectors 11:586CrossRef
go back to reference Dhiman RC, Raghavendra K, Kumar V, Kesari S, Kishore K (2003) Susceptibility status of Phlebotomusargentipes to insecticide in districts Vaishali and Patna. J Commun Dis 35:49–51PubMed Dhiman RC, Raghavendra K, Kumar V, Kesari S, Kishore K (2003) Susceptibility status of Phlebotomusargentipes to insecticide in districts Vaishali and Patna. J Commun Dis 35:49–51PubMed
go back to reference Foreman KJ, Lozano R, Lopez AD, Murray CJ (2012) Modeling causes of death: an integrated approach using CODEm. Popul Health Metr 10:1CrossRef Foreman KJ, Lozano R, Lopez AD, Murray CJ (2012) Modeling causes of death: an integrated approach using CODEm. Popul Health Metr 10:1CrossRef
go back to reference GBD (2019) Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2020). Lancet 396:1204–1222 GBD (2019) Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2020). Lancet 396:1204–1222
go back to reference Kishore K, Kumar V, Kesari S, Dinesh DS, Kumar AJ, Das P et al (2006) Vector control in leishmaniasis. Indian J Med Res 123:467–472PubMed Kishore K, Kumar V, Kesari S, Dinesh DS, Kumar AJ, Das P et al (2006) Vector control in leishmaniasis. Indian J Med Res 123:467–472PubMed
go back to reference Lainson R, Shaw JJ (1978) Epidemiology and ecology of leishmaniasis in Latin-America. Nature 273:595–600CrossRef Lainson R, Shaw JJ (1978) Epidemiology and ecology of leishmaniasis in Latin-America. Nature 273:595–600CrossRef
go back to reference Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128CrossRef Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128CrossRef
go back to reference Mathur P, Samantaray JC, Vajpayee M, Samanta P (2006) Visceral leishmaniasis/human immunodeficiency virus co-infection in India: The focus of two epidemics. J Med Microbiol 55:919–922CrossRef Mathur P, Samantaray JC, Vajpayee M, Samanta P (2006) Visceral leishmaniasis/human immunodeficiency virus co-infection in India: The focus of two epidemics. J Med Microbiol 55:919–922CrossRef
go back to reference Mubayi A, Castillo-Chavez C, Chowell G, Kribs-Zaleta C, Ali Siddiqui N, Kumar N et al (2010) Transmission dynamics and underreporting of Kala-azar in the Indian state of Bihar. J TheorBiol 262:177–185 Mubayi A, Castillo-Chavez C, Chowell G, Kribs-Zaleta C, Ali Siddiqui N, Kumar N et al (2010) Transmission dynamics and underreporting of Kala-azar in the Indian state of Bihar. J TheorBiol 262:177–185
go back to reference Muniaraj M (2014) The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities? Trop Parasitol 4(1):10–19CrossRef Muniaraj M (2014) The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities? Trop Parasitol 4(1):10–19CrossRef
go back to reference Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C et al (2012) GBD 2010: design, definitions, and metrics. Lancet 380:2063–2066CrossRef Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C et al (2012) GBD 2010: design, definitions, and metrics. Lancet 380:2063–2066CrossRef
go back to reference Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA et al (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:1005–1070CrossRef Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA et al (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:1005–1070CrossRef
go back to reference Singh R, Das RK, Sharma SK (2001) Resistance of sandflies to DDT in Kala-azar endemic districts of Bihar in India. Bull World Health Organ 79:793PubMedPubMedCentral Singh R, Das RK, Sharma SK (2001) Resistance of sandflies to DDT in Kala-azar endemic districts of Bihar in India. Bull World Health Organ 79:793PubMedPubMedCentral
go back to reference Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R et al (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53:e91–e98CrossRef Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R et al (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53:e91–e98CrossRef
go back to reference Sundar S, Chakravarty J (2012) Recent advances in the diagnosis and treatment of kala-azar. Natl Med J India 25:85–91PubMed Sundar S, Chakravarty J (2012) Recent advances in the diagnosis and treatment of kala-azar. Natl Med J India 25:85–91PubMed
go back to reference Thakur CP (2007) A new strategy for elimination of kala-azar from rural Bihar. Indian J Med Res 126:447–451PubMed Thakur CP (2007) A new strategy for elimination of kala-azar from rural Bihar. Indian J Med Res 126:447–451PubMed
go back to reference Thakur CP, Kumar M, Pandey AK (1991) Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res 93:103–110PubMed Thakur CP, Kumar M, Pandey AK (1991) Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res 93:103–110PubMed
go back to reference Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK (1993) Amphotericin B in resistant kala-azar in Bihar. Natl Med J India 6:57–60PubMed Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK (1993) Amphotericin B in resistant kala-azar in Bihar. Natl Med J India 6:57–60PubMed
go back to reference Thakur CP, Meenakshi Thakur AK, Thakur S (2009) Newer strategies for the kala-azar elimination programme in India. Indian J Med Res 129:102–104PubMed Thakur CP, Meenakshi Thakur AK, Thakur S (2009) Newer strategies for the kala-azar elimination programme in India. Indian J Med Res 129:102–104PubMed
go back to reference Werneck GL (2014) Visceral leishmaniasis in Brazil: Rationale and concerns related to reservoir control. Rev Saude Publica 48(5):851–856CrossRef Werneck GL (2014) Visceral leishmaniasis in Brazil: Rationale and concerns related to reservoir control. Rev Saude Publica 48(5):851–856CrossRef
go back to reference Werneck GL, Costa CHN, de Carvalho FAA, Pires e Cruz MdS, Maguire JH, et al (2014) Effectiveness of insecticide spraying and culling of dogs on the incidence of Leishmaniainfantum infection in humans: a cluster randomized trial in Teresina. Brazil. PLoS Negl Trop Dis 8(10):e3172CrossRef Werneck GL, Costa CHN, de Carvalho FAA, Pires e Cruz MdS, Maguire JH, et al (2014) Effectiveness of insecticide spraying and culling of dogs on the incidence of Leishmaniainfantum infection in humans: a cluster randomized trial in Teresina. Brazil. PLoS Negl Trop Dis 8(10):e3172CrossRef
go back to reference World Health Organization. (2007) Report of the fifth consultative meeting on leishmania-HIV coinfection, Addis Ababa, Ethiopia, 20–22 March 2007 (No. WHO/CDS/NTD/IDM/2007.5). World Health Organization World Health Organization. (2007) Report of the fifth consultative meeting on leishmania-HIV coinfection, Addis Ababa, Ethiopia, 20–22 March 2007 (No. WHO/CDS/NTD/IDM/2007.5). World Health Organization
Metadata
Title
India’s performance in controlling Visceral Leishmaniasis as compared to Brazil over past three decades: findings from global burden of disease study
Authors
Deepak Dhamnetiya
Ravi Prakash Jha
Shalini
Krittika Bhattacharyya
Publication date
01-12-2021
Publisher
Springer India
Published in
Journal of Parasitic Diseases / Issue 4/2021
Print ISSN: 0971-7196
Electronic ISSN: 0975-0703
DOI
https://doi.org/10.1007/s12639-021-01375-0

Other articles of this Issue 4/2021

Journal of Parasitic Diseases 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.